410: A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing

The biotech industry faces scrutiny over oversight failures and aggressive marketing practices. A fugitive posing as a biotech executive highlights critical gaps in corporate background checks, while investigations into the telemedicine provider LifeMD reveal concerns regarding rapid, high-volume GLP-1 prescribing and potential patient safety risks. Meanwhile, legal tensions escalate between Novo Nordisk and Eli Lilly over advertising claims in the competitive weight-loss drug market. Beyond these industry developments, Matt Wilsey, founder of Grace Science, details the arduous journey of developing a gene therapy for his daughter’s ultra-rare NGLY1 deficiency. Wilsey emphasizes the necessity of new regulatory pathways for ultra-rare diseases, noting that traditional clinical trial structures often fail to accommodate the unique needs of small patient populations and the urgency of life-saving interventions.